Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Canrib Olaparib Tablets 150 mg
Canrib Olaparib Tablets 150 mg is a targeted therapy used in the treatment of cancers with BRCA1 or BRCA2 gene mutations. Olaparib, the active component, is a potent PARP (poly ADP-ribose polymerase) inhibitor. By inhibiting PARP enzymes, Canrib prevents cancer cells from repairing their DNA, leading to cell death and tumor shrinkage.
Uses of Canrib Olaparib Tablets 150 mg
Ovarian Cancer: Used for maintenance treatment of recurrent ovarian cancer in patients with BRCA1 or BRCA2 mutations who are in response to platinum-based chemotherapy.
Breast Cancer: Effective in treating certain types of breast cancer with BRCA1 or BRCA2 mutations, particularly in patients who have undergone prior treatments.
Pancreatic Cancer: Used for maintenance treatment of pancreatic cancer with BRCA1 or BRCA2 mutations following platinum-based chemotherapy.
Prostate Cancer: Indicated for metastatic castration-resistant prostate cancer with BRCA1 or BRCA2 mutations after prior treatments.
Benefits of Canrib Olaparib Tablets 150 mg
Targeted Therapy: Specifically targets cancer cells with BRCA1 or BRCA2 mutations, offering a tailored approach to treatment.
Improved Outcomes: Has been shown to improve progression-free survival and overall response rates in patients with BRCA-related cancers.
Oral Administration: Convenient tablet form allows for easy administration and integration into daily routines.
Reduced Tumor Growth: Effectively slows down or halts tumor growth by inhibiting cancer cell repair mechanisms.
Long-Term Management: Suitable for long-term use in maintenance therapy, contributing to sustained disease control and better quality of life.
Mechanism of Action of Canrib Olaparib Tablets 150 mg
Olaparib works by inhibiting PARP (poly ADP-ribose polymerase) enzymes, which are involved in the repair of DNA single-strand breaks. Cancer cells, particularly those with BRCA1 or BRCA2 mutations, rely heavily on PARP for DNA repair. By blocking PARP activity, Canrib prevents these cells from repairing their damaged DNA, leading to the accumulation of DNA damage and ultimately causing cancer cell death. This mechanism helps to control tumor growth and improve patient outcomes.